HSD17B3: A Potential Drug Target for Psychiatric Disorders (G3293)

Target Name: HSD17B3

NCBI ID: G3293

HSD17B3

HSD17B3: A Potential Drug Target for Psychiatric Disorders

HSD17B3, also known as human short chain dehydrogenase family 17 member 3, is a gene that encodes a protein involved in the metabolism of neurotransmitters, such as dopamine and serotonin. The protein is a member of the HSD17B family, which is known for its role in redox reactions that involve the transfer of electrons from one molecule to another.

HSD17B3 is expressed in many different tissues throughout the body, including the brain, where it is involved in the production of neurotransmitters. It is also involved in the breakdown of other molecules that can be neurotoxic, such asopium and codeine.

Recent studies have suggested that HSD17B3 may be a drug target or biomarker for various psychiatric and neurological disorders, including depression, anxiety, and addiction. This is because the HSD17B family of proteins has been implicated in the pathophysiology of many psychiatric and neurological conditions, and HSD17B3 may be a key regulator of neurotransmitter synthesis and function.

One of the reasons for the potential utility of HSD17B3 as a drug target is its involvement in the production of neurotransmitters. Many psychiatric and neurological disorders are characterized by disruptions in neurotransmitter synthesis and function, which can lead to symptoms such as mood disorders, anxiety, and depression. HSD17B3 may be a target for drugs that can restore normal neurotransmitter synthesis and function, potentially treating these disorders.

Another potential application of HSD17B3 as a drug target is its involvement in the detoxification of neurotoxins. Many substances, such as opium and codeine, can be neurotoxic and cause addiction and other disorders. HSD17B3 may be involved in the breakdown of these substances, which could make it a potential target for drugs for addiction treatment.

In addition to its potential as a drug target, HSD17B3 has also been suggested as a biomarker for various psychiatric and neurological disorders. The HSD17B family of proteins has been implicated in the pathophysiology of many psychiatric and neurological conditions, including depression, anxiety, and addiction. By measuring the levels of HSD17B3 in brain tissue, researchers may be able to identify individuals at risk for these disorders and track their progress over time.

Overall, HSD17B3 is a protein that has the potential to be a drug target or biomarker for various psychiatric and neurological disorders. Further research is needed to fully understand its role in neurotransmission and its potential as a therapeutic target.

Protein Name: Hydroxysteroid 17-beta Dehydrogenase 3

Functions: Catalyzes the conversion of 17-oxosteroids to 17beta-hydroxysteroids (PubMed:8075637, PubMed:16216911, PubMed:27927697, PubMed:26545797). Favors the reduction of androstenedione to testosterone (PubMed:16216911, PubMed:27927697, PubMed:26545797). Testosterone is the key androgen driving male development and function (PubMed:8075637). Uses NADPH while the two other EDH17B enzymes use NADH (PubMed:26545797, PubMed:8075637, PubMed:16216911). Androgens such as epiandrosterone, dehydroepiandrosterone, androsterone and androstanedione are accepted as substrates and reduced at C-17 (PubMed:16216911). Can reduce 11-ketoandrostenedione as well as 11beta-hydroxyandrostenedione at C-17 to the respective testosterone forms (PubMed:16216911, PubMed:27927697)

The "HSD17B3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HSD17B3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets